Oncology Based In-Vivo CRO Market

Global Oncology Based In-Vivo CRO Market:

The global oncology based in-vivo CRO market size reached US$ 1.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 2.3 Billion by 2032, exhibiting a growth rate (CAGR) of 6.9% during 2024-2032. The rising prevalence of cancer, regulatory compliances, ongoing technological advancements, and the surging demand for personalized medicines are driving the market growth.

Oncology Based In-Vivo CRO Market Analysis:

• Major Market Drivers: The growing prevalence of cancer around the world represents one of the key factors driving the market. Moreover, governments of several countries across the globe are extensively investing in research and development (R&D) activities, which is driving industry’s growth.
• Key Market Trends: The wide availability of personalized treatment techniques, along with the expanding healthcare industry, is catalyzing the demand for oncology based in-vivo CRO worldwide. Additionally, there is an increase in the adoption of telehealth and virtual clinical trials in the healthcare industry to ensure the safety of cancer patients. This is projected to bolster the growth of the market.
• Competitive Landscape: Some of the prominent oncology based in-vivo CRO market companies in the market include Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec, and Xentech, among many others.
• Geographical Trends: According to the oncology based in-vivo CRO market dynamics, North America exhibits a clear dominance in the market. The prevalence of various types of cancer continues to increase in the region, driving oncology based in-vivo CRO market demand.
• Challenges and Opportunities: Regulatory and compliance burden, and the increasing demand for customized clinical trial protocols are hampering the market growth. However, AI-driven algorithms for data analytics, predictive modeling, and patient stratification enhance efficiency and decision-making in oncology research.
   

Oncology Based In-Vivo CRO Market Trends:

Rising Prevalence of Cancer

The rising prevalence of cancer is a significant driver behind the growth of the oncology-based in-vivo Contract Research Organization (CRO) market. Cancer continues to be a major public health challenge worldwide, with increasing incidence rates across various types of cancers. For instance, the IARC's 2022 study showed around 20 million new cancer cases and nearly nine million deaths worldwide, with lung and breast cancer being the most common. Similarly, according to an article published by the Union for International Cancer Control, cancer cases are projected to rise to 35 million by 2050. The complexity of cancer requires tailored treatment approaches, leading to a higher demand for clinical trials and research services provided by CROs. These factors are positively influencing the oncology based in-vivo CRO market revenue.

Increasing Emphasis on Personalized Medicine

The increasing emphasis on personalized medicine is a major driver behind the growth and evolution of the oncology-based in-vivo Contract Research Organization (CRO) market. For instance, according to Statista, personalized medical care, medicines, and diagnostics were estimated to account for around 40% of total revenue in 2022. Oncology is the most significant therapeutic area for personalized medicine. Tailoring treatments to individual patients improves efficacy, reduces adverse effects, and enhances overall treatment outcomes, driving the demand for CROs with expertise in personalized medicine, thereby positively influencing the oncology based in-vivo CRO industry forecast.

Technological Advancements

Increasing technological advancements are escalating the demand for oncology-based in-vivo Contract Research Organizations. Improved imaging modalities, such as PET-CT, MRI, and molecular imaging techniques have enabled better visualization and monitoring of tumors in vivo. For instance, in June 2024, Siemens Healthineers launched the Biograph Trinion, their latest PET/CT scanner, at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging. The scanner's detector is based on lutetium oxyorthosilicate (LSO) crystal elements and delivers high spatial resolution and an ultrafast time-of-flight performance of 239 picoseconds for small lesion detectability and effective sensitivity up to 128 cps/kBq, allowing for fast scans and low patient radiation doses. This enhances the ability to track disease progression and response to treatments more accurately. These factors are further bolstering the oncology-based in-vivo CRO market revenue.

Global Oncology Based In-Vivo CRO Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global oncology based in-vivo CRO market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on indication, model and application.

Breakup by Indication:

• Blood Cancer
• Solid Tumors
• Others
   

Solid tumors currently represent the largest market share

The report has provided a detailed breakup and analysis of the market based on the indication. This includes blood cancer, solid tumors, and others. According to the report, solid tumors represented the largest market segmentation.

According to the oncology-based in-vivo CRO market outlook, solid tumors are the most common type of cancer, encompassing a wide range of malignancies such as breast, lung, colorectal, and prostate cancers. Their prevalence ensures a large patient population for clinical trials, making them attractive for CROs and pharmaceutical companies. Moreover, there has been a significant increase in the number of cancer patients. For instance, the American Cancer Society, the major source of cancer statistics and data, estimated nearly 1,685,210 new cancer cases and 595,690 deaths in the United States in 2021. 

Breakup by Model:

• Syngeneic
• Xenograft
• Patient Derived Xenograft (PDX)
• Others
   

Currently, Patient Derived Xenograft (PDX) model accounts for the majority of the total market share

The report has provided a detailed breakup and analysis of the market based on the model. This includes syngeneic, xenograft, patient derived xenograft (PDX), and others. According to the report, the Patient Derived Xenograft (PDX) model accounts for the majority of the total market share.

According to the oncology-based in-vivo CRO market overview, PDX models involve implanting patient-derived tumor tissue into immunodeficient mice, thereby preserving the molecular and histological characteristics of the original tumor. This model closely mimics human tumor biology and heterogeneity, making it invaluable for studying cancer progression, metastasis, and treatment response. Moreover, these models are highly predictive of patient response to therapies, including chemotherapy, targeted therapy, and immunotherapy. Pharmaceutical companies and biotech firms rely on PDX studies to assess drug efficacy, optimize treatment regimens, and identify potential biomarkers for patient stratification.

Breakup by Application:

• Hospitals
• Rehabilitation Centers
   

The oncology-based in-vivo CRO market report has provided a detailed breakup and analysis of the market based on the application. This includes hospitals and rehabilitation centers.

Hospitals frequently collaborate with CROs to conduct clinical trials for evaluating new oncology treatments. CROs provide expertise in study design, protocol development, patient recruitment, and regulatory compliance, enabling hospitals to participate in cutting-edge research without diverting resources from patient care. While rehabilitation centers may participate in clinical trials focused on cancer survivors who require rehabilitation services to improve their quality of life post-treatment. CROs can support such trials by providing expertise in study design, outcome measures, and data management specific to this patient population.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

North America currently dominates the global market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

According to the oncology based in-vivo CRO market statistics, the rising incidence of cancer cases in North America continues to drive demand for innovative therapies and treatment options. For instance, the Globocan 2021 report estimated that nearly 2,281,000 new cancer cases were diagnosed in the United States in 2021, with almost 612,000 fatalities. Oncology-focused CROs play a critical role in advancing research and development efforts to address unmet medical needs across various cancer types. Moreover, continuous advancements in technology, including molecular profiling, genomic sequencing, imaging modalities (such as PET-CT and MRI), and high-throughput screening platforms, enhance the capabilities of CROs to conduct sophisticated in-vivo studies. These technologies enable precise characterization of tumors, identification of biomarkers, and evaluation of therapeutic efficacy, contributing to the growth of oncology based CRO services.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include: 

• Champions Oncology Inc.
• Charles River Laboratories International Inc.
• Crown Bioscience Inc.
• Eurofins Scientific
• Evotec SE
• ICON Plc
• Labcorp Drug Development (Laboratory Corporation of America Holdings)
• Living Tumor Laboratory
• Taconic Biosciences Inc.
• The Jackson Laboratory
• WuXi AppTec
• Xentech
   

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Oncology Based In-Vivo CRO Market Recent Developments:

• June 2024: Siemens Healthineers launched the Biograph Trinion, their latest PET/CT scanner, at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging.
• May 2024: The NHS launched a clinical trial in which patients would receive customized cancer vaccinations created by BioNTech and Genentech. The vaccine under study used mRNA technology and was personalized to the individual's cancer mutations.
• March 2024: Veeda Clinical Research Limited, a contract research organization (CRO) with a track record of successful drug development, acquired Heads, a privately held European CRO that conducts oncology clinical trials.

Oncology Based In-Vivo CRO Market Report Scope:

Key Benefits for Stakeholders:

• IMARC's report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the oncology based in-vivo CRO market from 2018-2032.
• The research study provides the latest information on the market drivers, challenges, and opportunities in the global oncology based in-vivo CRO market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the oncology based in-vivo CRO industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.